142 related articles for article (PubMed ID: 26669514)
1. Metabolic Fate of Hallucinogenic NBOMes.
Leth-Petersen S; Gabel-Jensen C; Gillings N; Lehel S; Hansen HD; Knudsen GM; Kristensen JL
Chem Res Toxicol; 2016 Jan; 29(1):96-100. PubMed ID: 26669514
[TBL] [Abstract][Full Text] [Related]
2. In vitro phase I metabolism of three phenethylamines 25D-NBOMe, 25E-NBOMe and 25N-NBOMe using microsomal and microbial models.
Grafinger KE; Stahl K; Wilke A; König S; Weinmann W
Drug Test Anal; 2018 Oct; 10(10):1607-1626. PubMed ID: 29971945
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Profile Determination of NBOMe Compounds Using Human Liver Microsomes and Comparison with Findings in Authentic Human Blood and Urine.
Temporal KH; Scott KS; Mohr ALA; Logan BK
J Anal Toxicol; 2017 Sep; 41(7):646-657. PubMed ID: 28472358
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens.
Halberstadt AL
Curr Top Behav Neurosci; 2017; 32():283-311. PubMed ID: 28097528
[TBL] [Abstract][Full Text] [Related]
5. 5-HT
Leth-Petersen S; Petersen IN; Jensen AA; Bundgaard C; Bæk M; Kehler J; Kristensen JL
ACS Chem Neurosci; 2016 Nov; 7(11):1614-1619. PubMed ID: 27564969
[TBL] [Abstract][Full Text] [Related]
6. Locomotor and discriminative stimulus effects of four novel hallucinogens in rodents.
Gatch MB; Dolan SB; Forster MJ
Behav Pharmacol; 2017 Aug; 28(5):375-385. PubMed ID: 28537942
[TBL] [Abstract][Full Text] [Related]
7. Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe.
Tang MH; Ching CK; Tsui MS; Chu FK; Mak TW
Clin Toxicol (Phila); 2014 Jun; 52(5):561-5. PubMed ID: 24779864
[TBL] [Abstract][Full Text] [Related]
8. Metabolic fate and detectability of the new psychoactive substances 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25B-NBOMe) and 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) in human and rat urine by GC-MS, LC-MS
Caspar AT; Brandt SD; Stoever AE; Meyer MR; Maurer HH
J Pharm Biomed Anal; 2017 Feb; 134():158-169. PubMed ID: 27915193
[TBL] [Abstract][Full Text] [Related]
9. 25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry.
Wohlfarth A; Roman M; Andersson M; Kugelberg FC; Diao X; Carlier J; Eriksson C; Wu X; Konradsson P; Josefsson M; Huestis MA; Kronstrand R
Drug Test Anal; 2017 May; 9(5):680-698. PubMed ID: 27448631
[TBL] [Abstract][Full Text] [Related]
10. Structure fragmentation studies of ring-substituted N-trifluoroacetyl-N-benzylphenethylamines related to the NBOMe drugs.
Almalki AJ; Clark CR; DeRuiter J
Rapid Commun Mass Spectrom; 2020 Feb; 34(4):e8593. PubMed ID: 31518025
[TBL] [Abstract][Full Text] [Related]
11. NBOMe: new potent hallucinogens--pharmacology, analytical methods, toxicities, fatalities: a review.
Kyriakou C; Marinelli E; Frati P; Santurro A; Afxentiou M; Zaami S; Busardo FP
Eur Rev Med Pharmacol Sci; 2015 Sep; 19(17):3270-81. PubMed ID: 26400534
[TBL] [Abstract][Full Text] [Related]
12. 25X-NBOMe compounds - chemistry, pharmacology and toxicology. A comprehensive review.
Herian M; Świt P
Crit Rev Toxicol; 2023 Jan; 53(1):15-33. PubMed ID: 37115704
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of (18)F-labeled 5-HT2A receptor agonists as PET ligands.
Herth MM; Petersen IN; Hansen HD; Hansen M; Ettrup A; Jensen AA; Lehel S; Dyssegaard A; Gillings N; Knudsen GM; Kristensen JL
Nucl Med Biol; 2016 Aug; 43(8):455-62. PubMed ID: 27209485
[TBL] [Abstract][Full Text] [Related]
14. Case series: toxicity from 25B-NBOMe--a cluster of N-bomb cases.
Gee P; Schep LJ; Jensen BP; Moore G; Barrington S
Clin Toxicol (Phila); 2016; 54(2):141-6. PubMed ID: 26621342
[TBL] [Abstract][Full Text] [Related]
15. Metabolic characterization of 25X-NBOH and 25X-NBOMe phenethylamines based on UHPLC-Q-Exactive Orbitrap MS in human liver microsomes.
Xiang J; Wen D; Zhai W; Zhao J; Xiang P; Ma C; Shi Y
J Pharm Biomed Anal; 2024 May; 242():116020. PubMed ID: 38359493
[TBL] [Abstract][Full Text] [Related]
16. 25CN-NBOMe Metabolites in Rat Urine, Human Liver Microsomes and
Šuláková A; Nykodemová J; Palivec P; Jurok R; Rimpelová S; Leonhardt T; Šíchová K; Páleníček T; Kuchař M
Metabolites; 2021 Mar; 11(4):. PubMed ID: 33807281
[No Abstract] [Full Text] [Related]
17. Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.
Cumming P; Scheidegger M; Dornbierer D; Palner M; Quednow BB; Martin-Soelch C
Molecules; 2021 Apr; 26(9):. PubMed ID: 33922330
[TBL] [Abstract][Full Text] [Related]
18. Metabolic profile determination of 25N-NBOMe in human liver microsomes by liquid chromatography-quadrupole time-of-flight mass spectrometry.
Seo H; Kim IS; Kim YH; Yoo HH; Hong J
Int J Legal Med; 2019 May; 133(3):833-841. PubMed ID: 30090972
[TBL] [Abstract][Full Text] [Related]
19. The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample.
Lawn W; Barratt M; Williams M; Horne A; Winstock A
J Psychopharmacol; 2014 Aug; 28(8):780-8. PubMed ID: 24569095
[TBL] [Abstract][Full Text] [Related]
20. Neurochemical and Behavioral Effects of a New Hallucinogenic Compound 25B-NBOMe in Rats.
Wojtas A; Herian M; Skawski M; Sobocińska M; González-Marín A; Noworyta-Sokołowska K; Gołembiowska K
Neurotox Res; 2021 Apr; 39(2):305-326. PubMed ID: 33337517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
